RADX · NASDAQ
Radiopharm Theranostics (RADX) Stock Price & Fundamentals
Radiopharm Theranostics (RADX) closed at $515.94 on Oct 9, 2026, down 1.51% from the previous close of $523.86.
Share price, past year
1Y −5.43%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $515.94 |
| Sep 30, 2026 | $518.99 |
| Aug 31, 2026 | $524.77 |
| Jul 31, 2026 | $519.17 |
| Jun 30, 2026 | $534.75 |
| May 29, 2026 | $518.28 |
| Apr 30, 2026 | $530.34 |
| Mar 31, 2026 | $547.86 |
| Feb 27, 2026 | $543.77 |
| Jan 30, 2026 | $561.76 |
| Dec 31, 2025 | $551.36 |
| Nov 28, 2025 | $570.63 |
| Oct 31, 2025 | $550.26 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- 3.5B
- Dividend yield
- —
- 52-week range
- $502.75 – $579.73
Market cap, P/E and dividend yield aren't shown for Radiopharm Theranostics yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US.
Financials
Radiopharm Theranostics reported revenue of $3.63M for fiscal 2025, up 1,114.27% from fiscal 2024.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Jun 30, 2025 | $3.63M | +1,114.3% | — | — | −$1.76 | — |
| FY2024ended Jun 30, 2024 | $299.23K | +2.4% | — | — | −$12.41 | — |
| FY2023ended Jun 30, 2023 | $292.36K | — | — | — | −$11.32 | −$23.25M |
Company profile
- Name
- Radiopharm Theranostics Ltd
- Ticker
- RADX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- Level 3, 62 Lygon Street, Carlton Vic, 3053
- Incorporated in
- C3
- Fiscal year ends
- June
- SEC CIK
- 0001949257
Recent SEC filings
- Sep 30, 2026
- Dec 10, 2025
- Sep 18, 2025
Frequently asked questions
What is Radiopharm Theranostics's stock price?
Radiopharm Theranostics (RADX) closed at $515.94 on Oct 9, 2026, down 1.51% from the previous close of $523.86.
How much revenue does Radiopharm Theranostics make?
Radiopharm Theranostics reported revenue of $3.63M for fiscal 2025, up 1,114.27% from fiscal 2024.
Sources and methodology
Fundamentals come from Radiopharm Theranostics Ltd's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures